Endoscopy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Endoscopy is a broad term for any procedure using a flexible, fibreoptic or video endoscope — a thin, flexible tube incorporating a light source, camera, and working channel for instruments — to visualise, sample, or treat the interior of the gastrointestinal (GI) tract. Upper GI endoscopy (oesophago-gastro-duodenoscopy or OGD, also called gastroscopy) passes the endoscope through the mouth and throat to examine the oesophagus, stomach, and duodenum. Lower GI endoscopy (colonoscopy) passes the endoscope through the anus and rectum to examine the entire colon to the ileocaecal valve and terminal ileum. Sigmoidoscopy examines only the sigmoid colon and rectum. Enteroscopy using specialised long scopes or capsule endoscopy extends examination to the small bowel.

Endoscopy serves dual purposes: diagnostic (visualising the mucosal lining of the GI tract, identifying abnormalities, and obtaining biopsy samples for histological analysis) and therapeutic (performing interventions including haemostasis for bleeding lesions, polypectomy, dilation of strictures, stent placement, foreign body removal, and endoscopic mucosal resection for early cancers). The procedure is performed in an endoscopy unit by a gastroenterologist, hepatologist, or trained surgeon, assisted by an endoscopy nurse who prepares medications, assists with equipment, and monitors the patient throughout.

Modern video endoscopy provides high-definition imaging with magnification, chromoendoscopy (staining of mucosa to highlight subtle lesions), narrow-band imaging (NBI, which highlights vascular patterns and dysplastic tissue), and artificial intelligence-assisted polyp detection. These technological advances have substantially improved the detection of early colorectal cancer, Barrett's oesophagus, and upper GI neoplasia compared to older endoscopes.

Upper GI endoscopy (gastroscopy) diagnoses and manages oesophageal conditions including reflux oesophagitis (graded by Los Angeles classification), Barrett's oesophagus (metaplastic change predisposing to oesophageal adenocarcinoma), oesophageal strictures (benign or malignant), oesophageal varices (dilated veins from portal hypertension, treated endoscopically with banding), Mallory-Weiss tears, and carcinoma. In the stomach, gastroscopy diagnoses peptic ulcers (Helicobacter pylori-associated, NSAID-induced), gastric cancer, gastritis, polyps, and arteriovenous malformations. Upper GI bleeding is the most urgent endoscopic indication — active bleeding from peptic ulcers, varices, and Dieulafoy lesions is treated endoscopically in the acute setting using injection therapy, thermocoagulation, clipping, or variceal banding.

Colonoscopy diagnoses and treats colorectal polyps (adenomatous polyps removed endoscopically by polypectomy to prevent colorectal cancer development), colorectal cancer (biopsied for staging, then referred for surgery), inflammatory bowel disease (Crohn's disease and ulcerative colitis — assessed by mucosal appearance, disease extent, and biopsy), diverticular disease, angiodysplasia (treated by argon plasma coagulation), colonic strictures (dilated or stented), and lower GI bleeding. Colonoscopy is the gold standard colorectal cancer screening procedure, with bowel preparation followed by systematic examination of the entire colon and polypectomy of any polyps found.

Upper GI endoscopy (gastroscopy) is indicated for: persistent dyspepsia over age 55 (alarm feature warranting cancer exclusion); dysphagia; unexplained iron deficiency anaemia; upper GI bleeding (haematemesis, melaena); suspected peptic ulcer; surveillance of Barrett's oesophagus; surveillance of gastric intestinal metaplasia; and unexplained weight loss. Colonoscopy is indicated for: colorectal cancer screening (all individuals over 50, or earlier with family history); investigation of lower GI symptoms including rectal bleeding, change in bowel habit, unexplained anaemia, or abdominal mass; inflammatory bowel disease diagnosis and surveillance; and surveillance colonoscopy at intervals after polypectomy (based on polyp type and number).

Contraindications to endoscopy include haemodynamic instability precluding safe sedation (urgent endoscopy for active bleeding may proceed with resuscitation ongoing); uncorrected severe coagulopathy (relative contraindication — therapeutic procedures such as biopsy or polypectomy require INR correction); active perforation or peritonitis (absolute contraindication to endoscopy, requiring emergency surgery); and inability to cooperate or consent without general anaesthesia. Patients on anticoagulants (warfarin, DOACs) require management according to procedure-specific bleeding risk: high-risk procedures (polypectomy, EMR) require anticoagulation reversal or bridging; low-risk procedures (diagnostic endoscopy, biopsy) may proceed on therapeutic anticoagulation.

Upper GI endoscopy requires no bowel preparation; patients fast for 6 hours before the procedure (nothing by mouth from midnight for morning lists). Throat spray (lignocaine) numbs the oropharynx for comfort during scope passage. Conscious sedation (intravenous midazolam 2–5 mg and/or fentanyl 50–100 mcg) is offered to all patients and is recommended for patient comfort; some patients prefer an unsedated examination with throat spray only. The endoscope is passed through the mouth, oropharynx, oesophagus, and into the stomach and duodenum. The examination takes 10–15 minutes for a standard diagnostic scope; therapeutic procedures (variceal banding, stricture dilation, haemostasis) extend the duration.

Colonoscopy requires thorough bowel preparation (usually a low-fibre diet 1–3 days before and laxative preparation solution such as polyethylene glycol 2–4 litres the day before, or split-dose preparation) to clear the colon of faecal material. Conscious sedation (midazolam and fentanyl) or propofol (providing deeper sedation requiring an anaesthetist — used for complex procedures or anxious patients) is standard. The colonoscope is advanced around the colon from the rectum to the ileocaecal valve, with CO2 gas insufflation to open the lumen. Carbon dioxide (rather than room air) is preferred as it is rapidly absorbed and reduces post-procedure bloating. Withdrawal time — the time spent carefully inspecting the colonic mucosa on scope withdrawal — is a quality indicator; minimum 6-minute withdrawal time is associated with higher adenoma detection rates.

Endoscopy provides unequalled direct visualisation of the GI mucosal surface with the ability to simultaneously obtain tissue samples and perform therapeutic interventions — capabilities unmatched by any imaging modality. For colorectal cancer screening, colonoscopy with polypectomy reduces colorectal cancer incidence by 40–80% by removing precancerous adenomatous polyps before malignant transformation, and reduces colorectal cancer mortality by 40–60% in screening populations through early-stage cancer detection. A high adenoma detection rate (ADR) — the proportion of screening colonoscopies in which at least one adenoma is found — is the primary quality metric, with each 1% increase in ADR associated with a 3% reduction in post-colonoscopy colorectal cancer risk.

For upper GI bleeding, endoscopic haemostasis achieves initial bleeding control in 80–90% of peptic ulcer haemorrhage cases, significantly reducing the need for emergency surgery and associated mortality. Endoscopic variceal banding for oesophageal variceal bleeding controls acute haemorrhage in 90–95% of cases and is superior to pharmacological therapy alone. Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) for early-stage oesophageal, gastric, and colorectal cancers provide curative resection with organ preservation in selected patients, avoiding major surgery and its morbidity. Patient experience of endoscopy, when performed with adequate sedation and skilled endoscopist technique, is generally well-tolerated.

Diagnostic endoscopy carries a very low complication rate. Perforation — the most serious complication — occurs in approximately 1 in 1,000–5,000 diagnostic upper GI endoscopies and 1 in 500–1,500 colonoscopies, requiring emergency surgical or endoscopic management. Risk is higher with therapeutic procedures (polypectomy, stricture dilation, ESD). Haemorrhage after polypectomy occurs in 1–2% of colonoscopic polypectomies, usually controlled endoscopically with clipping or coagulation, rarely requiring angiographic embolization or surgery. Infection is rare in immunocompetent patients undergoing standard endoscopy; scrupulous scope reprocessing and disinfection between patients is essential.

Cardiorespiratory complications from sedation — hypoxia, hypotension, cardiac arrhythmias — are the most common procedure-related adverse events, affecting 1–2% of procedures and managed by continuous pulse oximetry monitoring and supplemental oxygen. Aspiration of gastric contents (during upper GI endoscopy) is prevented by adequate fasting and positioning. Post-colonoscopy abdominal pain and bloating from gas insufflation is common and resolves within hours. Delayed perforation following polypectomy of large polyps (post-polypectomy syndrome — transmural thermal injury without immediate perforation) may present as localised peritonism 1–5 days post-procedure and is usually managed conservatively.

Patients receiving intravenous sedation must be accompanied by a responsible adult for discharge and are advised not to drive, operate machinery, or make important decisions for 24 hours. Recovery in the endoscopy unit takes 30–90 minutes after sedation, monitoring vital signs and conscious level before discharge. Patients may eat and drink normally after recovery, except when biopsy results for H. pylori are pending (no change required) or after upper GI haemostasis procedures (soft diet for 24 hours advised).

Biopsy results are typically available within 5–10 working days, communicated to the patient by letter or telephone and reviewed at the follow-up clinic or by the referring GP. Colonoscopy surveillance intervals are guided by the number and type of polyps found: patients with 1–2 small tubular adenomas are typically offered a 3–5-year surveillance interval; patients with 3 or more adenomas, any adenoma with high-grade dysplasia, or any adenoma 10 mm or larger require more frequent (1–3-year) surveillance colonoscopy. Barrett's oesophagus surveillance intervals depend on the length of Barrett's and presence of dysplasia, following NICE and BSG guidelines. Patients should receive a clear, written endoscopy report and surveillance plan at discharge.

Endoscopy costs vary significantly between healthcare systems. In the US, upper GI endoscopy (gastroscopy) costs USD 1,500–3,500 at an outpatient endoscopy centre, and USD 3,000–6,000 in a hospital setting; colonoscopy costs USD 2,000–4,500 for diagnostic examination, with polypectomy adding USD 500–1,500 per polyp removed. These costs are covered by Medicare and most private insurance for medically indicated procedures, with preventive colonoscopy (colorectal cancer screening) covered at 100% under the Affordable Care Act without patient cost-sharing. In the UK, NHS endoscopy services are free at point of care.

For patients seeking affordable endoscopy internationally, India and Thailand offer high-quality gastrointestinal endoscopy at 70–80% less than US private costs. Gastroscopy at a private hospital in India costs USD 80–200; colonoscopy (including bowel preparation) costs USD 150–350. Thailand offers colonoscopy for USD 200–500 at internationally accredited hospitals. Turkey and Malaysia are also cost-competitive at USD 200–400 for colonoscopy. JCI-accredited hospitals in all these destinations use modern video endoscopes, provide adequate sedation, and follow international standards for scope cleaning and disinfection. Patients scheduling elective endoscopy internationally should plan for any biopsy or polypectomy results to be communicated internationally to their home physician.

Non-endoscopic alternatives for upper GI investigation include barium swallow (for oesophageal and gastric anatomy — detecting strictures and reflux, but unable to biopsy), CT scan of the abdomen and pelvis (for masses, lymphadenopathy, and extraluminal pathology), and PET-CT (for cancer staging). However, none provides the direct mucosal visualisation or biopsy capability of endoscopy. For investigation of dyspepsia in low-risk younger patients, a test-and-treat strategy for H. pylori (urea breath test or stool antigen) without immediate endoscopy is evidence-based for those under 55 without alarm features.

For colorectal cancer screening, alternatives to colonoscopy include CT colonography (virtual colonoscopy — a CT scan of the colon requiring the same bowel preparation, providing equivalent polyp detection for large lesions but no therapeutic capability and requiring colonoscopy for any positive findings), flexible sigmoidoscopy (examining only the left colon — less thorough but lower risk and more acceptable to some patients), stool DNA testing (Cologuard in the US), and faecal immunochemical testing (FIT) — widely used as the primary screening test in the UK NHS Bowel Cancer Screening Programme. Positive FIT results require definitive colonoscopy. Capsule endoscopy (a small swallowable camera capsule) provides imaging of the entire small bowel — accessible to neither upper endoscopy nor colonoscopy — and is the investigation of choice for suspected small bowel bleeding or Crohn's disease.